EMA Authorised: Eylea (aflibercept) — Bayer AG

View source ↗

Summary

EMA authorises Eylea (aflibercept) for multiple ocular conditions including wet age-related macular degeneration and diabetic eye diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetes Complications Affecting the Eye
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: Bayer AG. Decision date: 15/01/2026